ENTX · Nasdaq · CIK 0001638097

Entera Bio Ltd.

Entera Bio Ltd.’s most recent SEC filing in our snapshot is a Form 8-K filed on Oct 27, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $42.0K and net income of -$11.4M, according to its XBRL data on EDGAR. Its EDGAR record lists 26 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$42.0K
Net income, FY2025
-$11.4M
Form 4 filings on record, past 12 months
26

Company overview

Legal name (as filed)
Entera Bio Ltd.
Ticker
ENTX
SEC Central Index Key (CIK)
0001638097
Business address
JERUSALEM
State or country of incorporation
Israel
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2879 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Entera Bio Ltd.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$571.0KFY2021$134.0KFY2022$0FY2023$181.0KFY2024$42.0KFY2025
Net income
-$12.2MFY2021-$13.1MFY2022-$8.9MFY2023-$9.5MFY2024-$11.4MFY2025
ENTX annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$571.0K$134.0K$0$181.0K$42.0K
Net income-$12.2M-$13.1M-$8.9M-$9.5M-$11.4M
Diluted EPS$0.47$0.45$0.31$0.25$0.25
Total assets$26.0M$13.1M$11.8M$9.4M$16.0M
Cash and equivalents$24.9M$12.3M$11.0M$8.7M$7.1M

XBRL tags used: revenue = Revenues; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

ENTX latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 27, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 7, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 27, 20268-KDirector or officer change; Regulation FD disclosure· period Oct 27, 2026Document · Index
Oct 14, 2026DEF 14ADefinitive proxy statement· period Oct 14, 2026Document · Index
Mar 18, 202120-FAnnual report of a foreign private issuer· period Dec 31, 2020Document · Index
Nov 10, 20216-KReport of a foreign private issuer· period Nov 10, 2021Document · Index

Recent SEC filings

The 40 newest documents filed by or about Entera Bio Ltd., by form type:

4 ×128-K ×6SCHEDULE 13G ×4DEF 14A ×2PRE 14A ×2EFFECT ×2424B3 ×23 ×1S-3 ×1D ×1S-8 ×110-Q ×1SCHEDULE 13D ×1DEFA14A ×1ARS ×1CORRESP ×1UPLOAD ×1
ENTX recent filings
FiledFormWhat it isOriginal
Oct 27, 20268-KDirector or officer change; Regulation FD disclosure· period Oct 27, 2026Document · Index
Oct 14, 2026DEF 14ADefinitive proxy statement· period Oct 14, 2026Document · Index
Oct 6, 20268-KDirector or officer change; Regulation FD disclosure· period Oct 6, 2026Document · Index
Sep 23, 2026PRE 14APRE 14A· period Sep 23, 2026Document · Index
Aug 28, 2026EFFECTEFFECTDocument · Index
Aug 28, 2026424B3424B3Document · Index
Aug 21, 2026S-3Simplified registration statementDocument · Index
Aug 21, 20263Initial statement of beneficial ownership· period Aug 18, 2026Document · Index
Aug 18, 20268-KRegulation FD disclosure; Other events· period Aug 18, 2026Document · Index
Aug 12, 2026DDDocument · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026Document · Index
Aug 7, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Aug 7, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 7, 20268-KResults of operations; Regulation FD disclosure· period Aug 7, 2026Document · Index
Aug 4, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 4, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 4, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 4, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 4, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Jul 28, 20268-KMaterial agreement; Unregistered equity sale; Director or officer change· period Jul 26, 2026Document · Index
Jul 16, 20268-KDirector or officer change; Charter, bylaws or fiscal year change; Shareholder vote results· period Jul 14, 2026Document · Index
Jul 16, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 14, 2026Document · Index
Jun 3, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Jun 3, 2026ARSARS· period Jun 3, 2026Document · Index
Jun 3, 2026DEF 14ADefinitive proxy statement· period Jun 3, 2026Document · Index
May 15, 2026EFFECTEFFECTDocument · Index
May 15, 2026424B3424B3Document · Index
May 14, 2026PRE 14APRE 14A· period May 14, 2026Document · Index
May 13, 2026CORRESPCORRESPDocument · Index
May 12, 2026UPLOADUPLOADDocument · Index
May 8, 20264Statement of changes in beneficial ownership (insider trade)· period May 7, 2026Document · Index
May 8, 20264Statement of changes in beneficial ownership (insider trade)· period May 7, 2026Document · Index

Insider filing activity

26 Form 4 filings appear in Entera Bio Ltd.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Biological Products, (No Diagnostic Substances)

All 61 companies in Biological Products, (No Diagnostic Substances)

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001638097 and XBRL company facts. Entera Bio Ltd. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.